Riyaz Shah

8.7k citations

49 papers · 4.0k · 3 hit papers · h-index 19

Impact in

Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 36
- Lung Cancer Treatments and Mutations 26
- Occupational and environmental lung diseases 5
- Lung Cancer Diagnosis and Treatment 5
Oncology 25
- Colorectal Cancer Treatments and Studies 9
- Lung Cancer Research Studies 8
- HER2/EGFR in Cancer Research 6
- Cancer Immunotherapy and Biomarkers 4

Co-authors: Kenneth J. O’Byrne (10 shared papers)Martin Schüler (7 shared papers)James Chih‐Hsin Yang (6 shared papers)Nobuyuki Yamamoto (7 shared papers)Tony Mok (7 shared papers)Vera Hirsh (7 shared papers)Jaafar Bennouna (4 shared papers)Ki Hyeong Lee (4 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Annals of Oncology (9 papers)Lung Cancer (7 papers)Journal of Thoracic Oncology (6 papers)Thorax (2 papers)
Partner nations: United Kingdom United States Taiwan

In The Last Decade

Riyaz Shah

46 papers receiving 3.9k citations

Riyaz Shah's Hit Papers

align trajectories log scale

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer 2023 · 142 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Communications
2018 Annals of Oncology
2013 Journal of Clinical Oncology

Peers

Countries citing papers authored by Riyaz Shah

Since Specialization

Citations

This map shows the geographic impact of Riyaz Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riyaz Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riyaz Shah more than expected).

Fields of papers citing papers by Riyaz Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riyaz Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riyaz Shah. The network helps show where Riyaz Shah may publish in the future.

Co-authors

The 25 scholars most cited alongside Riyaz Shah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Riyaz Shah Line = papers co-authored together Riyaz Shah links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler Hit paper breakdown →	2013	2478
2	Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study Annals of Oncology ·Suresh S. Ramalingam, Yi Cheng, C. Zhou, Y. Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, J. Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray Hit paper breakdown →	2018	272
3	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer Nature Communications ·Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam Hit paper breakdown →	2023	142
4	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology ·James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist	2012	136
5	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations Clinical Lung Cancer ·Riyaz Shah, J.F. Lester	2019	125
6	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial The Lancet Respiratory Medicine ·Gary Middleton, Kristian Brock, Joshua Savage, Rhys Mant, Yvonne Summers, John Connibear, Riyaz Shah, Christian H. Ottensmeier, Paul Shaw, Siow Ming Lee, Sanjay Popat, Colin Barrie, Gloria Barone, Lucinda Billingham	2020	116
7	Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy Journal of Thoracic Oncology ·Sophie Papa, Sanjay Popat, Riyaz Shah, A Toby Prevost, Rohit Lal, Blair Kp McLennan, Paul Cane, Loı̈c Lang-Lazdunski, Zaid Viney, Joel Dunn, Sally F. Barrington, David Landau, James Spicer	2013	62
8	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial The Lancet Oncology ·Vanesa Gregorc, Rabab Gaafar, Adolfo Favaretto, Francesco Grossi, Jacek Jassem, Andreas Polychronis, Paolo Bidoli, Marcello Tiseo, Riyaz Shah, Paul Taylor, Silvia Novello, Alberto Muzio, Alessandra Bearz, Laurent Greillier, Floriana Fontana, Giulia Salini, A. Lambiase, Mary O’Brien	2018	57
9	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology ·James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Robert M. Lorence, (unknown), Lecia V. Sequist	2012	53
10	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial Journal of Thoracic Oncology ·M. Nicolson, Dean A. Fennell, David Ferry, Kenneth J. O’Byrne, Riyaz Shah, Vanessa Potter, G. Skailes, Sunil Upadhyay, Paul Taylor, Valérie André, Tuan S. Nguyen, Scott P. Myrand, Carla Visseren‐Grul, Mayukh Das, Keith M. Kerr	2013	49
11	Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis Annals of Oncology ·Sendhilnathan Ramalingam, J.E. Gray, Yuichiro Ohe, Byoung Chul Cho, Johan Vansteenkiste, C. Zhou, Thanyanan Reungwetwattana, Ying Cheng, B. Chewaskulyong, Riyaz Shah, K.H. Lee, P. Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Rachel Hodge, Yuri Rukazenkov, Jean‐Charles Soria, David Planchard	2019	49
12	FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α Oncogene ·Riyaz Shah, J. Claire Ibbitt, Kari Alitalo, Helen C. Hurst	2002	47
13	A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Annals of Oncology ·Sanjay Popat, Alessandra Curioni‐Fontecedro, Varvara Polydoropoulou, Riyaz Shah, Mary O’Brien, A. Pope, P.M. Fisher, James Spicer, A. Roy, David Gilligan, Oliver Gautschi, Ernest Nadal, Wolf-Dieter Janthur, Rafael López Castro, Rosario García Campelo, Heidi Roschitzki‐Voser, Barbara Ruepp, Sylvie Rusakiewicz, Solange Peters, Rolf A. Stahel	2019	43
14	Expression of the multidrug resistance gene in human prostate cancer Urologic Oncology Seminars and Original Investigations ·Gurjeet Bhangal, Sarah Halford, J Wang, Rebecca Roylance, Riyaz Shah, Jonathan Waxman	2000	39
15	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2023	34
16	Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial Lung Cancer ·Penella J. Woll, Piers Gaunt, Sarah Danson, Nicola Steele, Samreen Ahmed, C Mulatero, Riyaz Shah, Jaishree Bhosle, Elizabeth Hodgkinson, Ben Watkins, Lucinda Billingham	2022	33
17	Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study Annals of Oncology ·Byoung Chul Cho, Y. Cheng, Changdong Zhou, Y. Ohe, Fumio Imamura, Meng C. Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray, S.S. Ramalingam	2018	28
18	Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer Lung Cancer ·Rohit Lal, Gunnar Hillerdal, Riyaz Shah, Barbara Crosse, Joyce Thompson, M. Nicolson, Anders Vikström, Vanessa Potter, Carla Visseren‐Grul, María Gabriela Lorenzo, Yulia Dyachkova, Nawel Bourayou, Yvonne Summers	2015	21
19	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial Annals of Oncology ·Gary Middleton, Kristian Brock, Yvonne Summers, John Connibear, Riyaz Shah, Christian H. Ottensmeier, Paul Shaw, S. Ming-Lee, Sanjay Popat, C. Barrie, Gloria Barone, Rhys Mant, Joshua Savage, Lucinda Billingham	2018	19
20	A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer British Journal of Cancer ·Mark Harries, C. Moss, Timothy Perren, Martin Gore, Geoff Hall, M. Everard, Roger A’Hern, I. Gibbens, A. Jenkins, Riyaz Shah, Christopher B. Cole, O Pizzada, Stan B. Kaye	2004	17

About Riyaz Shah

Riyaz Shah is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Genetics, having authored 49 papers that have together received 4.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Research Studies (8 papers), HER2/EGFR in Cancer Research (6 papers), Occupational and environmental lung diseases (5 papers), Lung Cancer Diagnosis and Treatment (5 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.9k citations), Oncology (1.9k citations), Cancer Research (500 citations), Molecular Biology (890 citations) and Pathology and Forensic Medicine (145 citations). Riyaz Shah has collaborated with scholars based in United Kingdom, United States and Taiwan. Frequent co-authors include Kenneth J. O’Byrne, Martin Schüler, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Tony Mok, Vera Hirsh, Jaafar Bennouna, Ki Hyeong Lee, Dan Massey and Lecia V. Sequist. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, Journal of Thoracic Oncology and Thorax.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Riyaz Shah

Impact in

Papers in i

In The Last Decade

Riyaz Shah

Riyaz Shah's Hit Papers

Peers

Countries citing papers authored by Riyaz Shah

Fields of papers citing papers by Riyaz Shah

All Works

About Riyaz Shah

Explore authors with similar magnitude of impact

Papers in